Liu Yan-Hui, Xu Fang-Ping, Zhuang Heng-Guo, Lai Kin-Chung-Chris, Xie Dan, Luo Dong-Lan, Li Li, Luo Xin-Lan, Xu Jie, Zhang Ming-Hui, Zhang Fen, Li Hiu-Ming
Department of Pathology and Laboratory Medicine, Guangdong Provincial People's Hospital, Guangzhou 510080, China.
Hum Pathol. 2008 Jun;39(6):875-84. doi: 10.1016/j.humpath.2007.10.013. Epub 2008 Apr 28.
Diffuse large B-cell lymphoma (DLBCL) can be subdivided into prognostically significant groups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 groups. In this study, tissue microarray slides composed of 163 de novo DLBCLs from Chinese patients were immunostained for CD20, CD10, Bcl-6, MUM1, CD138, Bcl-2, Ki-67, cyclin D3, geminin, and P27(Kip1). One hundred forty-nine of 163 DLBCLs could then be classified into GCB group (pattern A), activated GCB group (pattern B) and activated non-GCB group (pattern C) according to the expression of CD10, Bcl-6, MUM1, and CD138. Of the 149 cases, 40 (26%) showed pattern A expression and were grouped as GCB group, lower than reported frequency of the studies involving mostly Western population. Compared with cases with pattern A, those with pattern B (activated GCB group) and C (activated non-GCB group) more often presented with more aggressive tumors and a shorter survival time. These results indicate that most of DLBCLs from Chinese patients can be classified into prognostically different groups based on the antigenic expression models using a panel of GCB- and ABC-associated markers. Polymerase chain reaction analysis of t(14;18) showed that 11 of 64 cases were t(14;18)-positive, and most (10 of 11) of it occurred in the group with pattern A. The translocation was significantly associated with expression of Bcl-2 protein. The group with pattern B demonstrated more frequent expression of Ki-67, cyclin D3, geminin, and showed higher proliferative activity than the group with pattern A. These findings suggest that high proliferative activity of tumors with pattern B may be associated with aggressive tumor behavior and poor clinical outcome in patients with DLBCL.
弥漫性大B细胞淋巴瘤(DLBCL)可根据生发中心B细胞样(GCB)、活化B细胞样(ABC)和3型分组进一步细分为具有显著预后意义的组别。在本研究中,对来自中国患者的163例初发DLBCL组织微阵列切片进行了CD20、CD10、Bcl-6、MUM1、CD138、Bcl-2、Ki-67、细胞周期蛋白D3、geminin和P27(Kip1)的免疫染色。然后,根据CD10、Bcl-6、MUM1和CD138的表达情况,163例DLBCL中的149例可分为GCB组(A模式)、活化GCB组(B模式)和活化非GCB组(C模式)。在这149例病例中,40例(26%)表现为A模式表达,被归为GCB组,低于大多数涉及西方人群研究报告的频率。与A模式病例相比,B模式(活化GCB组)和C模式(活化非GCB组)病例的肿瘤侵袭性更强,生存时间更短。这些结果表明,使用一组与GCB和ABC相关的标志物,基于抗原表达模型,大多数来自中国患者的DLBCL可分为具有不同预后的组别。t(14;18)的聚合酶链反应分析显示,64例病例中有11例t(14;18)阳性,其中大多数(11例中的10例)发生在A模式组。该易位与Bcl-2蛋白的表达显著相关。B模式组Ki-67、细胞周期蛋白D3、geminin的表达更频繁,且增殖活性高于A模式组。这些发现提示,B模式肿瘤的高增殖活性可能与DLBCL患者的肿瘤侵袭性行为和不良临床结局相关。